Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection—Final Update of a Living, Rapid Review

Holmer, Haley K; Mackey, Katherine; Fiordalisi, Celia; Helfand, Mark

doi:10.7326/m22-1745

Cited by 11 publications

(8 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La infección previa proporciona una protección sustancial y sostenida contra la reinfección sintomática con la variante delta (SoE alta) y reduce el riesgo de enfermedad grave por las variantes ómicron (SoE moderada). La infec-ción previa protege menos contra la reinfección con ómicron en general (SoE moderada), pero la protección de las variantes anteriores disminuye rápidamente (SoE baja) (6) .…”

Section: Infección Y Reinfecciones Por Covid-19unclassified

El enigma del coronavirus – Reinfecciones por COVID-19, COVID prolongado – Vacunas bivalentes - La gestante – Derechos humanos y Ética

Romero

2022

Rev peru ginecol obstet.

View full text Add to dashboard Cite

show abstract

Section: Infección Y Reinfecciones Por Covid-19unclassified

El enigma del coronavirus – Reinfecciones por COVID-19, COVID prolongado – Vacunas bivalentes - La gestante – Derechos humanos y Ética

Romero

2022

Rev peru ginecol obstet.

View full text Add to dashboard Cite

show abstract

“…RT-PCR was the most consistent factor in non-seroconversion found in prospective cohort studies [ 10 , 11 ]. Studies also revealed that immunocompromised patients had a consistently lower prevalence of anti-SARS-CoV-2 antibodies compared to immuno-competent persons [ 12 ]. Liver transplant recipients showed a lower prevalence of anti-nucleocapsid and anti-spike IgG antibodies one year after SARS-CoV-2 infection [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave

Sočan

Prosenc

Mrzel

2023

IJERPH

View full text Add to dashboard Cite

We conducted a seroprevalence study using convenient residual sera samples from the Slovenian population collected after the end of the Omicron BA.1 pandemic wave. Serum samples were tested for spike glycoprotein (anti-S) and nucleocapsid protein (anti-N) antibodies. Participants’ data regarding confirmed infection and vaccination was obtained from national registries. Anti-S antibodies were detected in 2439 (84.1%) of 2899 sera from persons aged 0–90 years, with the lowest prevalence in the 0–17 age group. The proportion of anti-N positives was the lowest in the ≥70 age group. The proportion of anti-N positives was significantly higher among participants with confirmed past infection and among those who had never been vaccinated. In participants who had not been notified as infected and who had never been vaccinated, the seroprevalence of anti-S and anti-N antibodies was 53% and 35.5%, respectively. From the time of serum collection to mid-November 2022, 445 participants (15.3%) tested positive for SARS-CoV-2, with higher odds in seronegative participants, participants in the 40–59 age group, and those without notified previous infection. Vaccination status and gender had no significant effects on infection risk. This study underlines the importance of serosurveys in understanding the development of the pandemic.

show abstract

“…In the general population, prior infection with SARS‐CoV‐2 and vaccination reduce the risk of COVID‐19 recurrence and severe COVID‐19 5 . However, the SIREN study, a large multicenter, prospective cohort study of adult healthcare workers, found that immunity waned over time leaving people susceptible to SARS‐CoV‐2 reinfection 4,6,7 .…”

Section: Introductionmentioning

confidence: 99%

“…Waning immunity may be even more pronounced in immunocompromised lung transplant recipients (LTRs) who also have a reduced response to vaccination 8–12 . Furthermore, recent data suggest that vaccination and prior illness may confer less protection against reinfection with certain sublineages of the Omicron variant, even in otherwise healthy adults 5,13 …”

Section: Introductionmentioning

confidence: 99%

“…In the general population, prior infection with SARS-CoV-2 and vaccination reduce the risk of COVID-19 recurrence and severe COVID-19. 5 However, the SIREN study, a large multicenter, prospective cohort study of adult healthcare workers, found that immunity waned over time leaving people susceptible to SARS-CoV-2 reinfection. 4,6,7 Waning immunity may be even more pronounced in immunocompromised lung transplant recipients (LTRs) who also have a reduced response to vaccination.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prior SARS‐CoV‐2 infection may not alter the clinical course of COVID‐19 in lung transplant recipients: A single‐center experience

Sindu

Razia

Grief

et al. 2023

Clinical Transplantation

View full text Add to dashboard Cite

BackgroundIn the general population, prior infection with SARS‐CoV‐2 reduces the risk of severe COVID‐19; however, studies in lung transplant recipients (LTRs) are lacking. We sought to describe the clinical course of COVID‐19 recurrence and compare outcomes between the first and second episodes of COVID‐19 in LTRs.MethodsWe conducted a retrospective, single‐center cohort study of LTRs with COVID‐19 between January 1, 2022, and September 30, 2022, during the Omicron wave. We compared the clinical course of a second episode of COVID‐19 to that of the patients’ own first episode and to that of LTRs who developed a first episode during the study period.ResultsDuring the study period, we identified 24 LTRs with COVID‐19 recurrence and another 75 LTRs with a first episode of COVID‐19. LTRs who survived the initial episode of COVID‐19 had a similar disease course with recurrence, with a trend toward reduced hospitalization (10 (41.6%) vs. 4 (16.7%), p = .114). Furthermore, compared to LTRs with a primary infection during the Omicron wave, those with a reinfection had a non‐statistically significant trend toward reduced hospitalizations (aOR .391, 95% CI [.115–1.321], p = .131), shorter lengths‐of‐stay (median, 4 vs. 9 days, p = .181), and reduced intensive care unit admissions, intubations, and COVID‐19–related mortality.ConclusionsLTRs who survive the first episode of COVID‐19 are likely to have a similar clinical course with recurrent episodes. Although recurrent COVID‐19 may be milder, larger, well‐powered studies are needed to confirm this observation. Ongoing precautions are warranted.

show abstract

Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection—Final Update of a Living, Rapid Review

Cited by 11 publications

References 52 publications

El enigma del coronavirus – Reinfecciones por COVID-19, COVID prolongado – Vacunas bivalentes - La gestante – Derechos humanos y Ética

El enigma del coronavirus – Reinfecciones por COVID-19, COVID prolongado – Vacunas bivalentes - La gestante – Derechos humanos y Ética

Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave

Prior SARS‐CoV‐2 infection may not alter the clinical course of COVID‐19 in lung transplant recipients: A single‐center experience

Contact Info

Product

Resources

About